Mdma molecule:

Image from PubChem

Mdma Clinical Trials

Delivering Transcutaneous Auricular Neurostimulation to Improve Relapse Prevention in Opioid Use Disorder

To see complete record on, please visit this link

Id: NCT05053503

Organisation Name: Spark Biomedical, Inc.

Overal Status: Recruiting

Start Date: May 25, 2022

Last Update: October 21, 2022

Lead Sponsor: Spark Biomedical, Inc.

Brief Summary: The primary objective of this trial is to determine whether tAN can improve relapse prevention beyond that seen with extended-release injectable naltrexone during Phase II.

  • Opioid-use Disorder
  • Opioid Withdrawal

Total execution time in seconds: 0.34828996658325